Vicore Pharma Holding AB's stock is evaluated at a moderate level, reflecting its strong liquidity and financial resilience amidst continued net losses typical for biotech R&D phases. The technical analysis indicates potential short-term stability, while valuation remains tricky due to the negative P/E ratio. The absence of earnings call data and corporate events limits additional insights.

Vicore Pharma Holding AB (VICO) vs. iShares MSCI Sweden ETF (EWD)

Market Cap

kr1.81B

Dividend YieldN/A

Average Volume (3M)283.74K

Price to Earnings (P/E)―

Beta (1Y)0.55

Revenue GrowthN/A

EPS Growth63.85%

CountrySE

Employees33

SectorHealthcare

Sector Strength39

IndustryBiotechnology

Share Statistics

EPS (TTM)-0.44

Shares Outstanding234,579,120

10 Day Avg. Volume257,571

30 Day Avg. Volume283,739

Financial Highlights & Ratios

PEG Ratio-0.09

Price to Book (P/B)0.74

Price to Sales (P/S)0.00

P/FCF Ratio-10.69

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

Vicore Pharma Holding AB Business Overview & Revenue Model

Company DescriptionVicore Pharma Holding AB (VICO) is a Sweden-based pharmaceutical company focused on the development of innovative therapies for rare lung diseases and related indications. The company's core products are centered around its proprietary angiotensin II type 2 receptor (AT2R) agonist platform, which aims to address unmet medical needs in pulmonary and fibrotic diseases. Vicore Pharma's lead product candidate, VP01 (C21), is being developed for conditions such as idiopathic pulmonary fibrosis (IPF) and COVID-19-induced acute respiratory distress syndrome (ARDS).

How the Company Makes MoneyVicore Pharma Holding AB generates revenue primarily through the development and potential commercialization of its pharmaceutical candidates. The company's revenue model is largely dependent on the successful progression of its drug candidates through clinical trials, leading to potential licensing agreements, partnerships, or direct sales of approved therapies. Key revenue streams include milestone payments and royalties from strategic collaborations with larger pharmaceutical companies. Vicore Pharma may also seek funding through grants and public or private investments to support its research and development activities.

Vicore Pharma Holding AB Financial Statement Overview

Summary

Income Statement

Balance Sheet

Cash Flow

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	109.35M	0.00	0.00	0.00	0.00
Gross Profit	109.35M	-3.42M	-3.61M	-3.60M	-3.54M
EBITDA	-168.88M	-317.47M	-286.20M	-293.13M	-143.77M
Net Income	-168.63M	-310.94M	-288.42M	-296.48M	-146.86M
Balance Sheet
Total Assets	1.20B	497.84M	338.01M	451.17M	406.51M
Cash, Cash Equivalents and Short-Term Investments	1.16B	482.77M	261.74M	371.20M	318.62M
Total Debt	0.00	0.00	65.00K	320.00K	140.00K
Total Liabilities	73.78M	42.45M	48.92M	67.85M	52.00M
Stockholders Equity	1.13B	455.39M	289.08M	383.32M	354.51M
Cash Flow
Free Cash Flow	-164.95M	-448.62M	-302.92M	-265.17M	-122.94M
Operating Cash Flow	-164.95M	-249.58M	-299.92M	-265.17M	-119.94M
Investing Cash Flow	149.04M	-144.46M	74.00M	-7.00M	4.00M
Financing Cash Flow	834.06M	470.86M	187.04M	318.18M	176.97M

Vicore Pharma Holding AB Technical Analysis

Technical Analysis Sentiment

Negative

Last Price7.77

Price Trends

50DMA

8.15

Negative

100DMA

7.82

Negative

200DMA

8.00

Negative

Market Momentum

MACD

-0.17

Positive

RSI

43.24

Neutral

STOCH

48.12

Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:VICO, the sentiment is Negative. The current price of 7.77 is below the 20-day moving average (MA) of 8.20, below the 50-day MA of 8.15, and below the 200-day MA of 8.00, indicating a bearish trend. The MACD of -0.17 indicates Positive momentum. The RSI at 43.24 is Neutral, neither overbought nor oversold. The STOCH value of 48.12 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:VICO.

Vicore Pharma Holding AB Peers Comparison

Overall Rating

UnderperformOutperform

Sector (49)

Financial Indicators

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SANION	79 Outperform	kr1.39B	5.27	152.78%	―	1533.99%	―
HNSA	51 Neutral	kr2.38B	―		―	9.53%	41.19%
Sector *	49 Neutral	AU$2.49B	4.37	-64.25%	2.83%	36.51%	13.14%
SYNACT	48 Neutral	kr1.06B	―	-48.22%	―	―	67.70%
XSPRAY	47 Neutral	kr1.75B	―	-42.24%	―	―	-19.44%
BINV	46 Neutral	kr2.39B	―	-45.80%	―	-0.57%	-39.92%
VICO	45 Neutral	kr1.81B	―	-40.15%	―	―	63.85%

* Healthcare Sector Average

Performance Comparison

SE:VICO

Vicore Pharma Holding AB

7.73

-10.85

-58.40%

SE:HNSA

Hansa Biopharma AB

28.04

-20.94

-42.75%

SE:BINV

BioInvent International AB

36.35

4.25

13.24%

SE:SANION

Saniona AB

10.20

6.69

190.60%

SE:XSPRAY

Xspray Pharma AB

48.30

-30.26

-38.52%

SE:SYNACT

SynAct Pharma AB

21.20

12.28

137.72%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Apr 25, 2025